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a b s t r a c t 
The focus of pharmaceutical product development lies on assuring excellent product quality at the end 
of a cost-eﬃcient process. The Quality-by-Design (QbD) concept shifts the focus from quality assurance 
through testing to quality control by process understanding, resulting in very robust processes with high 
quality product. QbD was originally intended by authorities for biologics, where product quality proven 
completely by analytics is not desired. Product quality has to be controlled by means of appropriate 
processes and operations as well. 
These demands were developed in order to improve patients’ safety by optimal drug quality at more 
eﬃcient manufacturing processes reducing costs for healthcare systems. Furthermore, production of bio- 
logics includes feedstock variability and complex multi-step manufacturing processes in batch operation 
with variable lots – condition, which apply to botanicals as well. 
The use of rigorous (physico-chemical) process modeling in combination with QbD results in a high 
degree of process understanding. This offers, contrary to popular prejudices, great beneﬁt for manufac- 
turers with little extra effort during development. 
The methodical QbD-based approach is pursued to develop a process for extraction and puriﬁcation of 
10-deacetylbaccatin III from yew needles. A short history and key elements of the QbD-based application 
are introduced. 
The line of argument for basic process conception is described and initial risk assessment is shown. 
Typical raw material variation and vaporization are identiﬁed as causes of process variability, therefore, 
the implications to subsequent process steps are pointed out. Finally, inﬂuences of load and ﬂow rate on 
the chromatographic separation of 10-deacetylbaccatin III are shown to exemplify sensitivity of puriﬁca- 
tion design. 
© 2017 Tomsk Polytechnic University. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 

























The positive effects of plants on human health have been used
or centuries and are well accepted by patients to the present day.
he eﬃcacy of phytotherapeutics often results from a complex
omposition of substances [1,2] . The complexity of plant-based
rugs is one reason for the lack of satisfactory studies into their ef-
ect and causes problems for the deﬁnition and assurance of qual-
ty [3] . Although “good manufacturing practice” (GMP) is acknowl-
dged as an important tool in quality assurance, the regulatory ap-✩ Peer review under responsibility of Tomsk Polytechnic University. 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) roach for most problems varies between the competent agencies
e.g. FDA, EMA) [4,5] , which are responsible for the scientiﬁc evalu-
tion of the market applications. In addition, more political support
s needed to improve integration of traditional and complementary
edicine into health systems [6] . The World Health Organization
WHO) recognizes these challenges and proposes a new strategy
egulating traditional herbal medicines. [7] . 
Quality assurance is realized by the implementation of GMP
nd is well established in the industry for all types of medicines
8] . The Food and Drug Administration (FDA) reviewed the regu-
atory approach to GMP practices at that time and introduced a
odernized version with the focus on process risk determination,
isk mitigation, and risk control to promote the development of
obust and eﬃcient processes [9] . This approach has been adopted
nd further developed by the European Medicines Agency (EMA)
nd other communities and culminates in the “Quality by Design”n access article under the CC BY-NC-ND license. 
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g(QbD)-approach to process development for biologics. The QbD-
approach in its current form is shown in Fig. 1 . 
The implementation of QbD enables risk focused coopera-
tion between competent agencies and manufacturers and offers
a higher degree of process robustness and ﬂexibility (see Fig. 2 ).
Plants have in general a broad variety of compounds depend-
ing on growth and harvesting conditions. A suitable process de-
sign rated by the QbD principals ensures a robust process from
extraction to puriﬁcation even if the feedstock has a great vari-
ety. Over the last few years, a number of exemplary case stud-
ies have been published regarding different types of products
[10–12] . 
Also ﬁrst commercial applications containing QbD-elements
have been assessed and approved [13,14] . QbD was originally in-
tended by authorities for biologics, where product quality proven
completely by analytics is not desired. Product quality has to be
controlled by means of appropriate processes and operations as
well. 
These demands were developed in order to improve patients’
safety by optimal drug quality at more eﬃcient manufacturing pro-
cesses reducing costs for healthcare systems. Furthermore, produc-
tion of biologics includes feedstock variability and complex multi-
step manufacturing processes in batch operation with variable lots
– condition, which apply to botanicals as well. 
Transferring the QbD-approach to botanicals the natural vari-
ability of plant material needs to be addressed, establishes a qual-
ity standard and offers increased process knowledge, three aspects
with very high signiﬁcance for herbal products [15] . 
The focus on quality is important for phytopharmaceuticals,
not only for the safety of patients, but to promote standardiza-
tion and progress regarding the deﬁnition of quality of plant based
products. Fig. 2. Inside design sp. Example process 
The spectrum of herbal products ranges from edible plants,
eneral extracts to highly puriﬁed components, depending on the
umber and type of unit operation [16] . To cover the complete
pectrum of products, the production of 10-deacetylbaccatin III
10-DAB) was chosen to showcase the methodical approach to pro-
ess development including QbD-elements. 
The development process consists of a series of steps, shown in
ig. 3 . 
The QbD approach relies on solid process comprehension in or-
er to control product quality throughout the process. Especially,
he implementation of rigorous process models provides an effec-
ive method to establish the required process knowledge. They en-
ure comparability between process scales within rigorous models,
hich is why they represent the missing link, connecting process
isk assessment and process characterization [17–19] . 
A key concern regarding herbal products is the deﬁnition of
uality. The QbD-approach demands a deﬁnition of quality coher-
nt with the intended therapeutic application of the medication.
he “quality target product proﬁle” (QTTP) is based on pharma-
odynamics and pharmacokinetic studies, as well as toxicological
tudies, and usability. Based on the QTTP, relevant attributes of the
roduct need to be identiﬁed. 
The key quality attribute for the extraction of 10-DAB from yew
s the purity of the target component. The purity is deﬁned as
he amount and number of other components with similar elution
roperties during the ﬁnal separation in relation to the target com-
onent, as established in a previous work [20] . 
The example process for obtaining 10-DAB from yew, material
nd methods as well as analytics were proposed by Ref. [20] . A
eneral ﬂow sheet is shown in Fig. 4 . ace boundaries. 
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c  • Prior to extraction, the yew twigs and needles are shredded and
sieved (not shown in the ﬂowsheet). 
• After extraction with a mixture of acetone and water. 
• The acetone is recycled, resulting in the precipitation of chloro-
phyll. 
• 10-DAB is then puriﬁed from the aqueous concentrate by a one-
stepped liquid–liquid extraction with ethyl acetate which is suf-
ﬁcient to capture and purify most of the target component. 
• Finally, 10-DAB is isolated and further puriﬁed by batch chro-
matography utilizing reverse phase chromatography using ace-
tonitrile and water as eluents. 
In the following, the different QbD-elements are demonstrated
long the processing of the yew material: 
1. The risks of the preparation of plant materials are assessed. 
2. Based on this risk assessment, the impact factors on extraction
are evaluated. Fig. 4. 10-DAB produ3. The approach to process control is shown by deriving the de-
sign space for the ﬁnal separation step and pointing out the
linkage to prior unit operations. 
.1. Risk assessment of plant material preparation 
Risks regarding raw material are a main source of viability for
otanicals. The environment during growths and harvesting condi-
ions can result in very different com positions of active substances.
he concentration of 10-DAB has been shown to vary greatly be-
ween different parts and populations of yew trees [21] . 
The design of a process according to QbD-principles aims to un-
erstand the implications of variability for the product quality. The
rst step is the preparation of yew needles for solid–liquid extrac-
ion. The needles are shredded and sieved to allow a fast and eﬃ-
ient extraction. 
An exemplary, early risk assessment for the preparation pro-
edure prior to solid–liquid extraction is shown in Fig. 5 . Thection process. 
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p  Ishikawa-method is based on the cause and effect relation be-
tween quality and risk factors and can be used to get a general
overview [22] . The Ishikawa-diagram is quick and easy to under-
stand, which makes it ideal for eﬃcient risk assessment during
early development phases. 
Every revealed risk should be addressed during process devel-
opment. The inﬂuence on quality of human error, equipment and
environment can be mitigated by means of eﬃcient management,
by enforcing standard operation procedures or maintenance sched-
ules. Risks regarding process and materials, in this case shredding
and sifting, are the most relevant for process characterization. 
With increasing process comprehension, the valuation of risks
can change during the development. Therefore, the assessment
process should be reviewed over time, to ensure a conclusive risk
evaluation. It is important to note that risk assessment should not
exclude risks based on presumptions. Exclusion of risks without
proper, scientiﬁcally sound evaluation compromises overall process
robustness. All parameters must be considered until valid data are
generated to rule out their impact on quality. 
A comprehensive risk assessment is the basis for subsequent
process characterization. A popular method with a higher degree of
detail categorizes risks based on occurrence, impact and detectabil-
ity of the respective risk. The so called “failure mode and effects
analysis” (FMEA) can give additional information which is useful
during process characterization. 
The qualitative FMEA shown in Fig. 6 is based on the Ishikawa-
diagram for extraction, similar to the one shown in Fig. 5 . The
ranking of parameters according to occurrence, impact and de-
tectability is used to document the risk discussion process and
improve. 
Ranking risks according to the “risk priority number” (RPN) can
give an additional level of detail. The RPN is deﬁned as the product
of an impact, occurrence and detectability factor, ranging from 1 to
10, resulting in a number between 1 and 10 0 0 [23] . This kind of
quantitative risk ranking may lead to underestimation of low scor-
ing factors, as long as the risk factors are chosen presumptively. 
2.2. Impact factors of preparation on extraction of yew material 
On the basis of the comprehensive risk assessment described
before, the identiﬁed factors are investigated and ranked regardinghe amount of impact on the quality of the product. One of the
ost eﬃcient ways to determine the impact of parameters on
uality are experimental designs based on statistical methods
design of experiments, DoE). 
As shown in Fig. 5 the main process steps for preparation are
hredding and sieving of yew twigs. According to the FMEA, re-
ationships between particle size, solvent temperature, ﬂow rate
nd water content of plant material have been investigated using
 semi factorial DoE-approach including center point. The experi-
ental design consists of eight experiments and a triplicate center
oint, resulting in a total of 11 experiments. 
The semi factorial DoE can be used to evaluate risks by showing
nteractions between factors and allows identiﬁcation of factors,
hich impact the desired quality. Fig. 7 shows the impact of main
actors, with water content and particle size showing the highest
mpact. Based on these impact factors, the most robust process can
e derived. 
Factors with negligible impact on quality can be set to the most
onvenient value inside the investigated ranges. The remaining fac-
ors should be ranked based on their controllability and measura-
ility, which Fig. 8 exempliﬁes. Process robustness can be maxi-
ized by adjusting those factors to allow for more variability re-
arding the more challenging parameters: 
• First, ﬂow rate can be precisely controlled technically. 
• Second process temperature can be adjusted and measured pre-
cisely. 
• Water content of the solvent can be speciﬁed prior to extraction
and adjusted during mixing. These process parameters can be
classiﬁed as well controlled. 
• Particle size depends on plant morphology and ligniﬁcation.
These factors are more challenging to control, making a wider
acceptable range desirable for high process robustness. There-
fore, the risk priority of particle size and water content is ad-
justed. 
.3. Control strategy for separation of 10-DAB from yew extract 
Following risk assessment and risk ranking, a control strategy
as to be designed to guarantee the quality requirements of the
roduct. In order to control a process, the interactions between
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Fig. 6. Qualitative FMEA approach to risk assessment. 
Fig. 7. Impact factors on yield on purity of yew extract. 




















Fig. 9. Relation of tested space, design space and operation space. 
 
i  
t  rocess parameters and quality attribute have to be known inside
he characterized space. 
An expanded experimental design, based on the experimental
tudies during risk evaluation and ranking, is an eﬃcient way to
ncrease the availability of information. The resulting space, which
s controlled by this strategy, is usually referred to as “design
pace” (see Fig. 9 ). 
The application of previously introduced methods, i.e. risk as-
essment and sensitivity studies, has shown that separation may
e inﬂuenced by variability in ﬂow-rate, load, solvent composition
nd adsorbent properties among others [19] . According to QbD-
rinciples, a suitable solvent composition and adsorbent should be
hosen based on scientiﬁc insight and proven product knowledge.
creening of different phases and solvents was done using thin
ayer chromatography to determine suitable chromatographic con-
itions [24] . The best separation could be achieved on adsorbent
ith nonpolar properties. 
Solvent screening for modeling and optimization has shown
uitable solubility in solvents like acetone and ethanol [20] . pThe inﬂuences of ﬂow-rate and load on the separation are stud-
ed in semi-preparative scale (see Fig. 10 ). The method of separa-
ion is scaled up from analytic scale using the linear scale-up ap-
roach. 
142 L. Uhlenbrock et al. / Resource-Eﬃcient Technologies 3 (2017) 137–143 
Fig. 10. Design space of the chromatographic separation of 10-DAB. 




























































i  The assurance of process robustness is a main objective dur-
ing QbD-based process development. Multivariate parameter stud-
ies can be used to evaluate signiﬁcant risks, by increasing process
knowledge regarding the risk interaction. 
The main proportion of product is recovered between 1.25 and
1.5 column volumes (CV) after injection. The contour-diagram can
be derived from regression models based on the experimental de-
sign. The highlighted areas in Fig. 10 show the highest recovery
rate for all test conﬁgurations between 0.1 to 0.3 mg injected target
component and 20–40 mL/min ﬂow rate. The limitation of 0.125 mg
load has implications on the preceding process steps. Column load
is determined by the concentration of extract after liquid–liquid
extraction and the volume of injection. This connection is shown
in Fig. 11 . 
Inside the highlighted area, the injected amount of product will
be smaller 0.125 mg, meeting the requirements of the chromatog-
raphy design space. 
3. Conclusion 
The concept of risk , including risk assessment and control are
essential to the QbD-based development and offers the possibility
to develop eﬃcient and robust processes coping with natural vari-
ability of feedstocks in complex manufacturing procedures needing
manifold analytics in QA, only based on sound scientiﬁc data. 
The investigation of process parameters outside the normal op-
eration range, including the implication for subsequent process
steps, increases the ﬂexibility during operation and results in a
higher degree of overall process robustness and eﬃciency. Eﬃ-
ciency generates sustainability dealing with natural resources and
economy of healthcare systems under societal needs at improved
patients’ safety. 
The isolation of 10-DAB from yew can be used as an example
process to showcase risk assessment and risk evaluation for differ-
ent types of operations. The risks during preparation of plant material and extraction
re shown, utilizing basic risk assessment tools. Risk impact is
valuated by the example of solid–liquid extraction. Impact fac-
ors are generated using DoE, which can be used to minimize ex-
erimental effort and time during development and ensure statis-
ical signiﬁcance of the data. In this study a semi-factorial design
as used because it is suﬃcient to screen for major effects. A max-
mum of process robustness is ensured by ranking impact factors
ccording to controllability and measurability. For the extraction of
atural components from plants the natural variety of the plant
aterial plays an important role toward the total process. Never-
heless solid–liquid extraction is not capable to ensure the purity
f the product because of its relatively small selectivity. Hence this
nit operation has to be optimized to maximum yield in order to
se the natural resources in an eﬃcient way. Product purity and
herefore consumer security are assured by chromatography. The
ontrol strategy of the chromatographic separation including the
isk linkage of column load to the phase ratio during liquid–liquid
xtraction demonstrates the design space concept. 
The QbD-approach is on the way to become the new standard
n process development for biological pharmaceuticals. With the
pproval of the ﬁrst applications containing the QbD-approach for
rocess development, a milestone has been reached. 
The ICH-guideline Q8 describes QbD as an enhanced approach
o process development. The QbD-concept should not be seen as
 revolutionary approach to process design, but as an extension
25] . While additional effort during development is minimal for
he enhanced approach to process development, the gains regard-
ng process comprehension are clearly signiﬁcant. Furthermore, the
bD-approach harmonizes the language throughout industry and
nvolved agencies, reducing communication diﬃculties and conse-
uently improving the application process. 
The focus on risk based process development synergizes with
nitiatives by the agencies promoting continuous processing and






























































[  igorous physico-chemical modeling. The focus on data driven
ecision-making supports the use of physico-chemical modeling
or additional clarity, regarding possible interactions between risks
nd process parameters. Simultaneously, the integration of pre-
ictive process modeling signiﬁcantly reduces experimental ex-
enses, time and environmental impact of process development
aining sound quantitative process comprehension. The establish-
ent of validated small scale models bridges the gap between risk
ssessment and process characterization. 
The QbD-approach should not be seen as a burden imposed by
egulatory agencies but as a chance to integrate a higher degree
f ﬂexibility into process operation, in order to adapt reliably to
rocesses with natural variability. The advances in process analyt-
cal technologies (PAT), for example in the ﬁeld of spectroscopy,
mprove the possibilities to measure and control continuous pro-
esses. The combination of PAT and QbD is justiﬁably envisioned
y the regulatory agencies as the future of the pharmaceutical pro-
uction process. The application of QbD provides: 
• Robust and reliable processes, assuring product quality. 
• Solid process understanding, granting more ﬂexibility 
• Support for innovative methods, encouraging rigorous models. 
• Economic development of processes, reducing cost. 
• Risk focused development, supporting communication of regu-
latory and industry 
Besides the administrative deﬁnitions and lengthy explanations
f the guidelines, the intellectual short-cut of the approach could
e summed up as “continuous Good Science Practice (cGSP)” in or-
er to be able to ﬁle data-driven decisions. Applying QbD-methods
ombined with rigorous process modeling it could be exempliﬁed
hat QbD is more chance than obstacle for manufacturers. 
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